Carlyle Acquire Baxter Company for $3.5bn

The US medtech behemoth Baxter said that it has signed a final agreement to exit the renal care market. Carlyle, a worldwide investment firm, will acquire the business for $3.5 billion. The arrangement follows the company’s March 2024 statement that it planned to settle debts and improve overall performance by spinning up or selling off its renal care division, which would be called Vantive.

According to the firm, the board of directors decided that disposing the company to Carlyle will maximise value for Baxter owners and put Baxter and Vantive in the best possible situation for future growth.

The goods and services from Baxter’s portfolio will be used by the newly formed spin-out for peritoneal dialysis, hemodialysate, and supporting organ treatments, which includes continuous renal replacement therapy (CRRT).

Baxter CEO José Almeida statement: “Today’s announcement represents another critical step forward in the strategic transformation process we announced in early 2023. As a result of this proposed transaction, Baxter will emerge a more focused and more efficient company, better positioned to redefine healthcare delivery and advance innovation that benefits patients, customers and shareholders.”